KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Liabilities (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Total Liabilities data on record, last reported at $9.2 billion in Q3 2025.

  • For Q3 2025, Total Liabilities rose 13.5% year-over-year to $9.2 billion; the TTM value through Sep 2025 reached $9.2 billion, up 13.5%, while the annual FY2024 figure was $8.4 billion, 18.27% up from the prior year.
  • Total Liabilities reached $9.2 billion in Q3 2025 per REGN's latest filing, up from $8.3 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $9.2 billion in Q3 2025 and bottomed at -$28.2 billion in Q2 2024.
  • Average Total Liabilities over 5 years is $1.5 billion, with a median of $6.6 billion recorded in 2023.
  • Peak YoY movement for Total Liabilities: skyrocketed 143.09% in 2022, then plummeted 524.81% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $6.4 billion in 2021, then rose by 2.14% to $6.6 billion in 2022, then grew by 8.5% to $7.1 billion in 2023, then grew by 18.27% to $8.4 billion in 2024, then increased by 9.59% to $9.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $9.2 billion in Q3 2025, $8.3 billion in Q2 2025, and $8.2 billion in Q1 2025.